Episode 526: ESMO 2026 - The VOLGA trial in MIBC
The Uromigos
October 24, 2026
Michiel Van Der Heijden joins us after his ESMO discussion and Tom's presentation to discuss how these critical data reshape the MIBC landscape.
Speakers Brian Rini, Tom Powles, Michiel Van Der Heijden
Brian Rini (0:08)
Welcome, everyone, to our ESMO 2026, Uromigos podcast series. Tom and I are joined by Michiel Van Der Heijden, and we're going to talk about a Volga trial. Very exciting data, Tom, that you presented, and Michiel, you discussed really a final piece, or at least a piece of the puzzle of this perioperative space, this muscle-invasive space, I think much anticipated on the heels of the EV PEMBRO data.
Tom, I'm going to turn it over to you first, and just give us a rundown, a reminder of trial design and drugs and endpoints, and then Michiel, I'll ask you to comment as you did in your discussion.
Tom Powles (0:45)
Going back five years, muscle-invasive bladder cancer, even only a year, muscle-invasive bladder cancer was either cystexomy alone, which was actually the commonest approach.
Or neoadjuvant chemotherapy followed by a cystectomy. And there were obviously some adjuvant treatments, immune therapies, which are sometimes used too. And that was kind of the standard of care. And I think it's fair to say at ESMO last year, Christophe presented 303 and then Matt 304, and EV Pembro I think has superseded that. And that's nine cycles of perioperative EV Pembro. I think it's important to also recognize that this is not like sort of prostate cancer, post-prostatectomy or even kidney cancer, in that 60% of patients in the 303 trial, that was the EV Pembro study against cystectomy, they relapsed at two years. And so the control on cystectomy alone is not a great treatment. And the outcomes of this disease with cystectomy are pretty poor. EV Pembro revolutionized that, and we've seen before hazard ratios of OS of between 0.5 and 0.65 depending on the trial for EV Pembro. So I think that's the new standard of care. Now clearly, there are some nuances with platinum-based chemotherapy and we had, we did a previous podcast on that. The Volga trial is a three-arm study that has cystectomy as the control arm. It happened at about the same time. And essentially, there is a doublet arm. And in the doublet arm, we're giving Duvalimab for a year. So it's the same as the Pembopereoptive Pembrolizumab. But here, we're only giving the three neoadjuvant cycles. So it's three rather than nine cycles. And then in the triplet arm, we add in the CTA-4 inhibitor Tremelimumab to that neoadjuvant phase. So essentially, it's a three-arm study. Each arm has got about 230 patients. The primary endpoint was event-free survival. The secondary endpoint was overall survival. And the results were positive. Let's start with the doublet arm if I can. The hazard ratio for event-free survival was 0.51. The control arm performed not that dissimilarly to the 303 trial.
That's statistically significant. So it's obviously a big difference. And then there was also a significant overall survival advantage with a hazard ratio of 0.58. The grade 3 or 4 adverse event rate was 30%.
The path CR rate by investigator assessment was 45%. The CTDNA clearance rate was 60%.
And the quality of life data, for what it's worth, the study arm tracks above the control arm. But there are lots of issues with the quality of life data in this setting. The triplet arm was also slightly, I think it was interesting. It wasn't as positive as the doublet arm. The EFS hazard ratio was 0.61 compared to 0.51 for the doublet. And the OS was not significant at this point with a hazard ratio of 0.77. The median follow-up at the moment is 23 months. So it's relatively short, although I've got to tell you in this population, as I said before, these patients tend to relapse and things go wrong quite quickly. And what we found in the triplet arm was that we showed higher grade three or four adverse events, 40% versus 30%. And we actually showed double of immune-related toxicity, grade three or four, and less intensity of EV. And I think my conclusion of that is the triplet was challenging and didn't do quite as well as the doublet. And that's because EV and duvalumab are really, really active. You put in a third drug, tremolimumab, which is not as probably as active as those other two. Still active, but not as active as those other two. You disrupt, giving you really active therapies. And so while you might win four or five percent with the tremie, you might be losing ten or fifteen with the EV duvalumab. And that's why the results, I think, are relatively modest compared to the doublet.
So in summary, I think we've shown the doublet versus cystectomy is active. I think the results are positive and clinically meaningful overall survival.
That's attractive for patients because it's only three neoadjuvant cycles rather than nine perioperative cycles.
Read the other 27 minutes of this episode here.
$15 gets you this episode and 99 more. Credits never expire. After checkout, one link brings you back here to read it.
Not what you expected? Full refund within 14 days.
Thousands of transcripts fetched by people building searchable podcast archives
Fetch transcripts with code
The same credits work from a script or an AI agent. The demo key returns a sample episode in full, no card needed:
curl -H "x-api-key: pt_demo" \
https://spoken.md/transcripts/1000651996090Markdown with the speakers named, for your notes, your knowledge base, or anything that makes HTTP calls.
From $0.10 per transcript. No subscription. Credits never expire. Prices exclude VAT, added at checkout for EU customers. Not what you expected? Email us within 14 days with 20 or fewer credits used and we refund the pack in full.
Using your own key:
curl -H "x-api-key: YOUR_KEY" \
https://spoken.md/transcripts/1000797933106